Esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker and its application

An esophageal cancer and marker technology, applied in the fields of genetic engineering and oncology, can solve the problems of lack of specific and sensitive molecular markers, different molecular biological changes, lack of early recurrence and metastasis of esophageal cancer, etc. The effect of improving sensitivity and specificity, simple method, and convenient operation

CN103173449AActive Publication Date: 2013-06-26河南普诺易生物制品研究院有限公司 +1
1 Cites 8 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2013-06-26

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker and its application, and concretely discloses an miRNA marker has-miR-382, an application of the miRNA marker in the making of an esophagus cancer postoperative early-stage recurrence and prognosis auxiliary diagnosis kit, an application of the primer of the esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker in the making of the esophagus cancer postoperative early-stage recurrence and prognosis auxiliary diagnosis kit, and the esophagus cancer postoperative early-stage recurrence and prognosis auxiliary diagnosis kit of the primer of the esophagus cancer postoperative early-stage recurrence and prognosis related miRNA marker. A screening method in the invention is simple and is convenient to operate, and the screened has-miR-382 can auxiliarily determine the prognosis or death risk of an esophagus cancer patient, and promotes the development of the esophagus cancer diagnosis and treatment.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a miRNA marker related to the early recurrence and prognosis of esophageal cancer after surgery, and also relates to the application of the marker, belonging to the fields of genetic engineering and oncology. Background technique

[0002] Esophageal cancer (Esophageal carcinoma, EC) is a common malignant tumor of the digestive tract, accounting for the second place in the death of tumors in various parts of the digestive system. The world dies from this disease every year, reaching 300,000 people, of which about 150,000 people die in China every year. It is the country with the highest incidence rate of esophageal cancer in the world. Although great progress has been made in chemotherapy, radiotherapy, and concurrent chemoradiotherapy for esophageal cancer in recent years, surgery is still the most important treatment for esophageal cancer. However, the treatment effect is not ideal, and the 5-year survival rate is only about ...

Examples

Embodiment

[0028] 1. Sample selection

[0029] Two paraffin specimens were selected from the First Affiliated Hospital of Xinxiang Medical College from 2006 to 2007 with the same pathological stage and significantly different prognosis and survival. These two specimens were both paraffin specimens made from tumor samples of primary lesions surgically resected for the first time. At the same time, the normal esophageal mucosa 8 cm away from the edge of the tumor tissues of the two paraffin samples were selected as controls. In 2 cases, no distant metastasis was diagnosed by physical examination and imaging before operation, and no radiation therapy or chemotherapy was received before operation. Both cases underwent esophageal cancer resection + thoracic and abdominal two-field lymph node dissection, and neck anastomosis was performed manually. Postoperative chemotherapy was given twice, and postoperative pathological examination revealed well-differentiated squamous cell carcinoma of the ...

experiment example 1

[0068] Experimental example 1. Verification of expression difference of has-miR-382 in patients with esophageal cancer with the same stage but different prognosis

[0069] 1. Sample selection

[0070] Selected 46 cases of paraffin wax specimens from the First Affiliated Hospital of Xinxiang Medical College from 2006 to 2009 with the same pathological stage and significant differences in prognosis and survival. There was no distant metastasis in the imaging diagnosis of the examination machine, and no radiation therapy or chemotherapy was received before operation. Among them, 18 cases were specimens of esophageal cancer that were alive 5 years after surgery and had a good prognosis, and 28 cases were specimens of esophageal cancer that had recurred early within 1 year after surgery and had a poor prognosis. The patient information is shown in Table 7. At the same time, the normal esophageal mucosa with the same pathological stage and 8 cm away from the edge of the tumor tissu...

experiment example 2

[0099] Experimental example 2. Analysis of has-miR-382 expression level and risk score method for early recurrence and prognosis of esophageal cancer after surgery

[0100] The SPSS17.0 database was established and analyzed, and Kaplan-Meier was used to analyze the survival curve of has-miR-382 expression. Taking P figure 2 shown.

[0101] Cox univariate risk analysis was performed on the prognosis, gender, age, TNM stage, postoperative T, N0-N1 stage, tumor size, degree of differentiation and expression of has-miR-382 in patients with esophageal cancer. The results are shown in Table 9 Show. The results showed that the patient's prognosis (P=0.000), postoperative T (p=0.008), tumor size (p=0.007) and has-miR-382 expression (P=0.021) were significantly correlated with the patient's survival time.

[0102]Table 9 The expression of has-miR-382 and the risk score method of early recurrence and prognosis of esophageal cancer after univariate analysis

[0103]

[0104] The ab...